KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Receivables - Other: 2017-2024

Historic Receivables - Other for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $9.1 million.

  • Amneal Pharmaceuticals' Receivables - Other rose 208.08% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 208.08%. This contributed to the annual value of $9.1 million for FY2024, which is 7.93% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Receivables - Other stood at $9.1 million for FY2024, which was down 7.93% from $9.9 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Receivables - Other registered a high of $33.1 million during FY2022, and its lowest value of $9.1 million during FY2024.
  • For the 3-year period, Amneal Pharmaceuticals' Receivables - Other averaged around $17.4 million, with its median value being $9.9 million (2023).
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Receivables - Other soared by 1,611.70% in 2020, and later crashed by 70.03% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Receivables - Other stood at $17.1 million in 2020, then crashed by 42.92% to $9.8 million in 2021, then surged by 239.13% to $33.1 million in 2022, then plummeted by 70.03% to $9.9 million in 2023, then decreased by 7.93% to $9.1 million in 2024.